DermaSensor

DermaSensor is a point-of-care device intended to assist primary care providers in the early detection of skin cancer by utilizing multi-wavelength light to analyze reflectance spectra from suspicious lesions with an integrated AI classifier. The underlying science leverages spectral differences between benign and malignant tissues to offer a 'Monitor' or 'Investigate' recommendation, supplementing traditional diagnostic pathways for patients aged 40 and older.

DermaSensor is a handheld device designed for patients aged 40 and older to assess suspicious skin lesions. The device operates by applying multi-wavelength light to a lesion and measuring its reflectance spectra. This spectral data is then processed by an integrated Artificial Intelligence (AI) classifier, which provides a binary output: 'Monitor' for lesions likely to be benign, or 'Investigate' for lesions that may be malignant, thereby aiding primary care providers in their decision-making process regarding dermatological referrals. The AI classifier within DermaSensor was developed using a training set comprising thousands of lesions with histological confirmation. Clinical data indicates the device achieves approximately 96% sensitivity in detecting common skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. It is intended as a point-of-care tool to enhance early skin cancer detection by supplementing, but not replacing, traditional diagnostic methods such as biopsy or specialist dermatological assessment.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the specificity of the DermaSensor device, and how does its false positive rate impact referral patterns in a primary care setting?; How does the device's performance vary across different skin types, lesion morphologies (e.g., nodular vs. superficial spreading melanoma), and anatomical locations?; Beyond the binary 'Monitor' or 'Investigate' output, does the AI provide any quantitative risk score or confidence level that could further aid clinical decision-making?; What are the long-term data on how DermaSensor integration into primary care workflows affects patient outcomes, such as time to diagnosis for malignant lesions or reduction in unnecessary biopsies?; Are there plans to expand the AI model's training to include rarer skin malignancies or to differentiate between subtypes of common skin cancers?